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PSA Bounce was seen in 7.2% of patients. Acute urinary retention 
rate was 4%. Mean Acute increase in IPSS scores was 6 points. 
There was no difference in acute GU toxicity between EBRT or 
brachytherapy boost doses. There was also no difference in acute 
toxicity if brachytherapy was done before or after EBRT. The rate 
of Late Grade 2+ GU toxicity was 13%. The rate of late Grade 2+ 
GI toxicity was 1.8%. 
Conclusions: This data shows excellent biochemical control 
comparable to most large series with HDR brachytherapy boost 
for prostate cancer. Toxicity was similar between dose regimens 
and further justifies moving towards hypofractionated regimens.  
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Purpose: Previous studies using T2-weighted (T2w) MRI showed 
significant uncertainties in brachytherapy target delineation, 
with conformity index for gross tumour volume at brachytherapy 
(GTVB) of 0.58-0.60. We examined the feasibility and utility of 
dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted 
MRI (DWI), and FDG PET imaging for brachytherapy target 
delineation in patients with locally advanced cervical cancer. 
Methods and Materials: Twenty-two patients with cervical 
squamous cell carcinoma or adenocarcinoma (12 Stage IB/IIA, 7 
IIB, 3 III/IVA) treated with definitive chemoradiation had DWI, 
DCE-MRI, and FDG PET/CT scan after brachytherapy applicator 
insertion, in addition to standard T2w MRI at 3T. GTVB and high-
risk clinical target volume (HRCTV) were contoured first on the 
axial T2w images by a single observer on the day of 
brachytherapy. The DWI, DWI-derived apparent diffusion 
coefficient map, DCE-MRI and FDG PET images were then 
reviewed, and if indicated the GTVB and/or HRCTV were 
modified to define the target more accurately, and/or include 
areas of suspected disease on DWI/DCE-MRI/FDG PET not obvious 
on T2w MR. Target delineation was performed by a second 
observer after brachytherapy treatment in the same manner. 
The primary endpoints were (1) feasibility; and (2) utility, 
determined by (a) the number of patients whose target volumes 
were modified based on DWI/DCE-MRI/FDG PET, and (b) 
interobserver variability using the conformity index (ratio 
between common and union volumes of a pair of contours by 
observers). 
Results: It was feasible to perform DWI, DCE-MRI and FDG PET 
without significantly delaying patients' brachytherapy 
treatment. The conformity indices for T2w-derived GTVB and 
HRCTV were 0.57 and 0.76, respectively. Eleven (50%) patients' 
T2w-GTVB contours were modified on the day of brachytherapy 
(Observer 1): seven based on better demarcation of the GTVB on 
DWI/DCE-MRI/FDG PET, and four based on DWI/DCE-MRI/FDG 
PET showing residual disease not well visualized on T2w MRI. 
GTVB was modified in 17 patients by Observer 2 (11 and six, 
respectively). Overall, Observer 1 found DWI, DCE-MRI and FDG 
PET useful for GTVB modification in nine, 11 and five patients, 
respectively; and in nine, 14 and eight patients respectively for 
Observer 2. For those patients, incorporation of functional 
imaging improved the conformity index for GTVB from 0.57 to 
0.66 (p < 0.001). HRCTV was modified in three and eight patients 
by Observers 1 and 2, respectively, with a trend towards higher 
conformity index using functional imaging (0.71 to 0.76, p = 
0.06). 
Conclusions: DWI, DCE-MRI and FDG PET imaging decreased 
interobserver variability in GTVB target delineation. Given data 
from retroEMBRACE showing the importance of minimum dose to 
the GTVB, reducing uncertainties in its delineation is of great 
importance. 
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Purpose: Over a multi-fraction course of intra-cavitary cervical 
brachytherapy (BT), treatment response will cause the HR-CTV 
to shrink. If BT is planned to conform to the HR-CTV, this change 
may impact dose to normal structures, having implications for BT 
scheduling and planning. 
Methods and Materials: Fifty patients receiving 26 Gy/4# or 
30Gy/5# intracavitary brachytherapy between January 1, 2014 
and December 31, 2015 as part of radical treatment for cervix or 
endometrial cancer were included in this study. Each fraction of 
BT was individually planned with the oncologist having available 
information from initial staging, EUA on day BT, intra-operative 
trans-abdominal u/s and CT-simulation. With a median time of 
27.1 days (range 9-43) between first and last implant, HR-CTV 
volume, point A dose and D2cc of bladder, rectum, sigmoid and 
small bowel were calculated for the first and last implant and 
compared using a paired t-test. 
Results: Between the first and last BT, HR-CTV volume shrank 
from a median of 23.7 cc to 15.5 cc (p = 0.001). This was 
associated with a reduction in median Point A dose from 520 cGy 
to 485.5 cGy (p = 0.002). Rectal, sigmoid and small bowel doses 
were not significantly different between the first implant and 
last with median D2cc of 221.5 versus 192.0 cGy (p = 0.9), 360.5 
versus 361.0 cGy (p = 0.3) and 173.0 versus 154.5 cGy (p = 0.9), 
respectively. However, median bladder D2cc dropped from 530.0 
to 486.0 cGy (p = 0.0003)  
Conclusions: Modest reductions in the size of the HR-CTV over 
the course of cervical BT are measurable and resulted in 
reductions in point A dose as well as bladder D2cc. These 
observations suggest that conforming BT to HR-CTV rather than 
point A and delivering BT after the cervix has been cytoreduced 
can potentially reduce bladder side effects. 
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Purpose: Cervical cancer remains to be a major health problem 
and cancer-related cause of death among women in developing 
countries such as Iran where the most cases are diagnosed in 
locally advanced stage. This cross sectional-analytic study aims 
to report outcome 154 patients with carcinoma of cervix were 
treated with external beam radiation therapy (EBRT) and high-
dose rate (HDR) brachytherapy with cobalt 60 (Co-6o) remote 
after loading system. 
Methods and Materials: A total of 154 patients with the 
international federation of gynecologist and oncologist (FIGO) 
Stages I-IVA with histopathologically confirmed carcinoma of 
cervix, followed by the radiation-oncology ward of Shohada-e-
Tajrish Hospital in Tehran, Iran, between February 2008 and 
March 2015. They were completed their scheduled EBRT and HDR 
brachytherapy with Co-60 remote after loading system. Out of 
this, 132 patients completed their standard follow up protocol. 
They were analyzed for three-year disease-free survival (DFS), 
three-year overall survival (OS) incidence of acute and late 
complications for HDR brachytherapy. 
Results: Fourteen patients (9.1 %) were in Stage I (FIGO 
classification), 8 (5.2%) were in Stage IIA, 26 (16.9%) were in 
Stage IIB, 100 (64.9%) were in Stage III, and 6 (3.9 %) were in 
Stage IVA. The follow up duration was between 6 - 60 months 
with a median of 38 months. Overall rectal and bladder 
treatment toxicity rates were 33.7%. The three-year DFS rate 
was 85.7%, 70.7 %, 41% and 16.6% for Stages I, II, III, IVA 
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respectively. Favourable prognostic factors in univariate and 
multivariate analysis were early stage, tumour size < 4 cm (after 
adjusting for the residual disease after radiation), no pelvic 
lymph node involvement and one week gap between EBRT and 
HDR brachytherapy in three-year DFS (p = 0.001, p = 0.012, p = 
0.005, p = 0.005 respectively). The three-year OS rate was 85.7%, 
76.4%, 42%, and 33.3% for Stages I, II, III, and IVA, respectively. 
Favourable prognostic factors in univariate and multivariate 
analysis were early stage, tumour size < 4 cm, no pelvic lymph 
node involvement, one week gap between EBRT and HDR 
brachytherapy and no distant metastasis (during the follow up) 
in three-year OS (p = 0.001, p = 0.002, p = 0.002, p = 0.002, p = 
0.001 respectively). 
Conclusions: HDR brachytherapy with Co-60 remote after 
loading system was successful and it showed HDR brachytherapy 
in treating patients with carcinoma of cervix was effective after 
EBRT with acceptable rectal and bladder complications. 
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Purpose: The quality of prostate brachytherapy implant depends 
on accurate placement of seeds in their intended locations. This 
study will investigate intraoperative factors that potentially 
contribute to seed placement inaccuracy in prostate 
brachytherapy. 
Methods and Materials: Intraoperative video images of the 
brachytherapist’s hands motion and needle insertions during the 
implant procedure were acquired for analysis. Using video 
analysis software, maximum and average insertion velocities 
were measured. Number of needle insertion attempts and the 
use of brachytherapist’s other hand to manipulate the lateral 
needle movements were also recorded. Magnitude of seed 
displacements from their target location were measured in 
ultrasound images acquired following completion of each implant 
using VariSeed treatment planning software. 
Results: Fifteen patients agreed to undergo this study. 1619 
iodine-125 seeds were inserted using 357 needles. 1197 seeds 
were confidently identified in the ultrasound images and 
included in the analysis. Mean overall displacement was 0.49 cm 
(0 to 2.1 cm, 95% CI = 0.48-0.52). Six hundred and fourteen seeds 
were delivered with a single pass and 583 seeds were delivered 
with > 1 passes (range 1 to 6). Mean maximum velocity was 12.17 
cms-1 (range 4 to 28 cms-1) and mean average velocity was 4.77 
cms-1 (range 0.4 to 17.4 cms-1). Seven hundred and forty-seven 
seeds were delivered with manipulation of the needle by the 
brachytherapist’s other hand. Generalized linear model (GLM) 
was used to determine the factors contributing to seed 
displacement and found that maximum insertion velocities < 12 
ms-1 was associated with a decrease in seed displacements by 
0.049cm compared to maximum speed of > 12 cms-1 (95%CI:-
0.09;-0.01, p = 0.0121). Other evaluated factors did not show any 
no statistically significant correlation with seed displacement: 
average speed (95%CI:-0.05;0.02, p = 0.4947), lateral 
manipulation of needle (95%CI:-0.04;0.04, p = 0.9264) and 
number of needle passes (95%CI:-0.02;0.01, p = 0.8907). 
Conclusions: This study identified that needles inserted with 
lower maximum velocities were associated with less seed 
displacement. Lateral manipulation of needle, number of passes 
and average speed did not show statistically significant 
correlation with the magnitude of seed displacement. 
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Purpose: Interstitial brachytherapy (ISBT) implantation has 
advantages over standard intracavitary techniques in locally-
advanced gynecological malignancies. The insertion of implanted 
catheters directly into tumour tissue enables higher radiation 
dose conformality and normal tissue sparing. Nevertheless, this 
procedure can be associated with pain and discomfort because 
of its invasiveness. The goal of this study is to assess pain and 
opioid use by patients implanted with a perineal ISBT applicator 
for treatment with brachytherapy. 
Methods and Materials:  Thirty-nine patients treated with high-
dose rate ISBT using a perineal template from September 2014 
to January 2016 were included in a prospective registry trial. 
Median age was 65 (range 23-88) and the cohort included 13 
cervical cancers patients, 11 primary vaginal cancers, 11 
recurrent endometrial cancers, one vulvar cancer and three 
palliative treatments. Patient characteristics (age, obesity, 
diabetes, use of anti-depressants/anxiolytics) and technical ISBT 
implantation data (number of needles, depth of implantation and 
pelvic organ intrusion) were collected. Quantity of opioid use 
(morphine-oral-equivalent-dose (MoED) per day) and maximum 
pain scores (0-10) at rest or with movement were evaluated. 
Paired t-test was used for opioid comparison between first and 
second implantations. Regression linear analysis was used to 
identify independent predictors of opioid use. 
Results: The majority of patients (34) were initially treated with 
a course of external beam radiation therapy with a median dose 
of 45 Gy to the pelvis. Twenty-two patients had a single ISBT 
implantation while 17 had a second implantation, one week 
later. The median number of needles used for each implant was 
17 (8-26) and a median of three (2-5) fractions of ISBT treatments 
were delivered. Mean MOeD use per day was statistically higher 
for the second (55 mg versus 81 mg) procedure as compared to 
the first insertion (p < 0.05). Maximum pain score at rest or 
movement was also higher after the second implantation (5/5 
versus 7/6). Age (continuous variable) and numbers of implanted 
catheter needles (dichotomized by median- 17 or less versus > 
17) were found to be significant predictors of opioid use for the
first procedure. Depth of catheter insertion and pelvic organ 
intrusion were not correlated to opioid use or pain score. 
Conclusions: Interstitial brachytherapy patients require 
adequate analgesia with opioids after applicator insertion and 
inpatient stay. The second ISBT implantation is associated with 
greater opioid consumption and higher median pain scores 
(moderate versus moderate to severe). The number of implanted 
needles correlated with increase in opioid use, whereas age had 
an inverse correlation. 
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Purpose: Magnetic resonance (MR) is considered the gold-
standard imaging modality to guide cervical cancer 
brachytherapy (BT), however introducing this modality into a BT 
process can be challenging. The Models of Care Working Group 
within Cancer Care Ontario’s Gynaecological Community of 
Practice (GYN CoP) of the Radiation Treatment Program focused 
on developing strategies for Ontario patients to access this 
technology and expertise. The aim of this study is to identify 
current models of care for cervical cancer brachytherapy (ccBT) 
